AQST Insider Trading
Insider Ownership Percentage: 7.85%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $429,964.28
Aquestive Therapeutics Insider Trading History Chart
This chart shows the insider buying and selling history at Aquestive Therapeutics by year and by quarter.
Skip ChartChart Data in Insider Trading History Table
Aquestive Therapeutics Share Price & Price History
Current Price: $3.17
Price Change: ▼ Price Decrease of -0.045 (-1.40%)
As of 01/22/2025 12:43 PM ET
Aquestive Therapeutics Insider Trading History
SEC Filings (Institutional Ownership Changes) for Aquestive Therapeutics (NASDAQ:AQST)
32.45% of Aquestive Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.
Institutional Buying and Selling by Quarter
This chart shows the instiutional buying and selling at AQST by year and by quarter.
Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
Aquestive Therapeutics Institutional Trading History
Data available starting January 2016
Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. Its proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. The company's proprietary pipeline of complex molecule product includes AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; and Anaphylm, an epinephrine sublingual film for the emergency treatment of allergic reactions, including anaphylaxis. In addition, it develops Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey.
Read More on Aquestive Therapeutics
Volume
237,562 shs
Average Volume
1,563,106 shs
Market Capitalization
$288.58 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
2.71
Who are the company insiders with the largest holdings of Aquestive Therapeutics?
Who are the major institutional investors of Aquestive Therapeutics?
Which major investors are buying Aquestive Therapeutics stock?
Within the previous quarter, AQST stock was acquired by institutional investors including:
- Janney Montgomery Scott LLC
- SG Americas Securities LLC